10x Genomics Q4 revenue rises

10x Genomics

12/02/2026 21:23

Overview

Single cell biology firm's Q4 revenue rose 1% yr/yr

Net loss for Q4 narrowed to $16.3 mln from $49.0 mln yr/yr

Operating expenses for Q4 fell 18% yr/yr

Outlook

10X Genomics expects 2026 revenue between $600 mln and $625 mln

Company anticipates up to 4% revenue growth in 2026, excluding non-recurring revenue

Result Drivers

GROSS MARGIN IMPROVEMENT - Q4 gross margin increased due to lower inventory write-downs, royalty costs, and warranty costs

CASH POSITION - Ended the year with $523.4 mln in cash and equivalents, an increase of $130.0 mln over the prior year

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 EPS
-$0.13
Q4 Net Income
-$16.30 mln
Q4 Gross Margin
68.00%
Q4 Operating Income
-$19.50 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 13 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

Wall Street's median 12-month price target for 10X Genomics Inc is $18.00, about 6% below its February 11 closing price of $19.15

Press Release: ID:nPn6Fl4MLa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)